RUNX2 inhibition halts bone loss in menopause

RUNX2 inhibition via the small molecule CADD522 slowed age-related bone mineral density loss in an ovariectomy-induced mouse model, preserving trabecular microarchitecture after eight weeks of dosing (25 mg/kg, three times weekly). The mechanism works by enhancing osteoblast activity—bone-building cells that progressively lose dominance to osteoclasts with advancing age, driving the remodeling imbalance characteristic of osteoporosis. Cross-species pharmacokinetic studies confirmed oral bioavailability, favorable short-term tolerability, and direct target engagement validated by cellular thermal shift assays. For the longevity-conscious reader, this represents a meaningful shift: against bisphosphonates (atypical fracture risk), daily-injection PTH derivatives, and hormone replacement (breast and ovarian cancer associations), an orally bioavailable antagonist emerges with a cleaner tolerability profile and concurrent metabolic benefits that extend beyond skeletal integrity alone.